
|Articles|March 31, 2008
FDA requires REMS plan for 25 drugs, biologics
FDA issues a notice requiring the manufacturers of 25 high-risk drugs and biologics to submit a REMS plan.
Advertisement
In a notice published in the March 27
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Embedded Pharmacists Are Vital Yet Underutilized in Diabetes Care
2
Executive Order Calls for Realignment of Childhood Vaccines
3
The Prodigious PBM Pivot: How Supply Chain Entities Will Move Forward After CAA 2026
4
Heat and Older Adults: What Pharmacists Need to Know
5





























































